← CytoDyn Inc. (CYDY) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
CytoDyn Inc. (CYDY)
Pharmaceutical Preparations · market cap $290M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
8
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
CytoDyn Inc. (CYDY) is a clinical-stage pharmaceutical company with a market cap of approximately $478M at $0.35/share and roughly 1.37 billion shares outstanding. Its lead asset is leronlimab (PRO 140), a humanized monoclonal antibody targeting CCR5, in Phase 3 development for HIV and earlier-stage trials in NASH, COVID-19, and oncology indications. The company carries only $15.7M in cash — roughly 3.8 months of runway — against $24.9M in net debt, with no near-term catalysts on the calendar and no sell-side analyst coverage.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| leronlimab 700 mg | Phase 2 | Nonalcoholic Steatohepatitis (NASH) |
| PRO 140 (350 mg) | Phase 3 | HIV |
| Leronlimab (700mg) | Phase 2 | Coronavirus Disease 2019 |
| PRO 140 (humanized monoclonal antibody to CCR5) | Phase 2 | HIV -1 Infection |
| Optimized Background Regimen | Phase 3 | HIV |
| PRO 140 | Phase 3 | HIV-1-infection |
| Leronlimab | Phase 2 | Solid Tumor, Adult |
| 350 mg leronlimab | Phase 2 | Metastatic Colorectal Cancer (mCRC) |
Price & technical context
3-month
-16.7%
6-month
-25.9%
12-month
-22.5%
52-wk range
$0.19–$0.37
vs 50-day MA
-2.6%
vs 200-day MA
-22.9%
Realized vol
64.6%
Max drawdown
-55.5%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CYDY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.